Aytu BioPharma Inc
Research Aytu BioPharma Inc (AYTU) on Bullrun: market cap USD 21.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAYTU
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 21.79M
- Financial periodFY2026
- RevenueUSD 57.57M
- Revenue growth-13.3%
- Net income-USD 14.25M
- Free cash flowUSD 3.25M
- Gross margin64.0%
Valuation Snapshot
latest market cap is USD 21.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 57.57M | -USD 14.25M | USD 3.25M | 64.0% | -1.16 | USD 26.31M | USD 17.03M | USD 35.27M |
| FY2025 | USD 66.38M | -USD 13.56M | -USD 2.17M | 69.0% | -2.16 | USD 30.95M | USD 12.75M | USD 18.97M |
| FY2024 | USD 65.18M | -USD 15.84M | -USD 1.72M | 75.3% | -2.86 | USD 20.01M | USD 12.73M | USD 27.72M |
| FY2023 | USD 107.40M | -USD 17.05M | -USD 5.13M | 62.0% | -5.11 | USD 22.99M | USD 14.80M | USD 39.36M |
| FY2022 | USD 96.67M | -USD 108.78M | -USD 28.82M | 54.1% | -74.01 | USD 19.36M | USD 18.81M | USD 44.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 21.79M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 27.91M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 10.49M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 15.81M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 11.86M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 40.51M | n/a | n/a | n/a |
About Aytu BioPharma Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aytu BioPharma Inc's market cap?
Aytu BioPharma Inc's market capitalization is USD 21.79M.
What does Aytu BioPharma Inc do?
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.